It's as I said; It was likely determined that PFS failed but Powers chose to continue on with OS with the understanding no more patients would be enrolled. The FDA then likely said Do what you want it's your money and the research is always valuable but no approval based on outcome. So, she focuses on EU instead. Sells Cognate and builds Advent.
From CTR-EU:
The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
E.5.2.1 Timepoint(s) of evaluation of this end point: October 2020
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): Patients will be treated by their physicians according to the current standard of care.
P. End of Trial
P. End of Trial Status: Temporarily Halted
With regards to the invisible CEO suggest you brush up on 10b-5.
Market Data 
Markets 
AI
